Cindy Delgado

Cindy Delgado

Auto-generated profile, based on publicly available information

Cindy Delgado

Division of Digestive Health and Liver Diseases,Department of Medicine,University of Miami Miller School of Medicine,Miami,Florida,USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in JAMA
Verified
Journal Article
Open access
PDF file
AHAlan W. Heldman
Alan W. Heldman
DDDarcy L. DiFede
Darcy L. DiFede
JFJoel E. Fishman
Joel E. Fishman
JZJuan P. Zambrano
Juan P. Zambrano
BTBarry H. Trachtenberg
Barry H. Trachtenberg
JHJoshua M. Hare
Joshua M. Hare
Recent preclinical studies and clinical trials suggest that bone marrow–derived cell preparations, including mononuclear bone marrow cells1-6 and mesenchymal stem cells,7,8 ameliorate left ventricular (LV) remodeling with acute4,7 myocardial infarction (MI) and chronic1-3,5,8,9 ischemic cardiomyopathy. An effective antiremodeling, proregenerative treatment for ischemic cardiomyopathy would address a major unmet need for many patients. By virtue of their greater differentiation potential,10 the culture-expanded mesenchymal stem cells constituent of bone marrow is speculated to have potential for forming ectopic tissue11 or stimulating tumors12 but could also have greater antifibrotic and proregenerative effects than bone marrow mononuclear cells.13 An unresolved issue is whether mesenchymal stem cells have similar safety and possibly greater efficacy than bone marrow mononuclear cells.8

1 February 2017 in JACC
Verified
Journal Article
Open access
JHJoshua M. Hare
Joshua M. Hare
DDDarcy L. DiFede
Darcy L. DiFede
ARAngela C. Rieger
Angela C. Rieger
VFVictoria Florea
Victoria Florea
ALAna M. Landin
Ana M. Landin
AHAlan W. Heldman
Alan W. Heldman
Although human mesenchymal stem cells (hMSCs) have been tested in ischemic cardiomyopathy, few studies exist in chronic nonischemic dilated cardiomyopathy (NIDCM). The authors conducted a randomized comparison of safety and efficacy of autologous (auto) versus allogeneic (allo) bone marrow-derived hMSCs in NIDCM. Thirty-seven patients were randomized to either allo- or auto-hMSCs in a 1:1 ratio. Patients were recruited between December 2011 and July 2015 at the University of Miami Hospital. Patients received hMSCs (100 million) by transendocardial stem cell injection in 10 left ventricular sites. Treated patients were evaluated at baseline, 30 days, and 3-, 6-, and 12-months for safety (serious adverse events [SAE]), and efficacy endpoints: ejection fraction, Minnesota Living with Heart Failure Questionnaire, 6-min walk test, major adverse cardiac events, and immune biomarkers. There were no 30-day treatment-emergent SAEs. Twelve-month SAE incidence was 28.2% with allo-hMSCs versus 63.5% with auto-hMSCs (p = 0.1004 for the comparison). One allo-hMSC patient developed an elevated (>80) donor-specific calculated panel reactive antibody level. The ejection fraction increased in allo-hMSC patients by 8.0 percentage points (p = 0.004) compared with 5.4 with auto-hMSCs (p = 0.116; allo vs. auto p = 0.4887). The 6-min walk test increased with allo-hMSCs by 37.0 m (p = 0.04), but not auto-hMSCs at 7.3 m (p = 0.71; auto vs. allo p = 0.0168). MLHFQ score decreased in allo-hMSC (p = 0.0022) and auto-hMSC patients (p = 0.463; auto vs. allo p = 0.172). The major adverse cardiac event rate was lower, too, in the allo group (p = 0.0186 vs. auto). Tumor necrosis factor-α decreased (p = 0.0001 for each), to a greater extent with allo-hMSCs versus auto-hMSCs at 6 months (p = 0.05). These findings demonstrated safety and clinically meaningful efficacy of allo-hMSC versus auto-hMSC in NIDCM patients. Pivotal trials of allo-hMSCs are warranted based on these results. (Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis in Dilated Cardiomyopathy [PoseidonDCM]; NCT01392625).

18 September 2017 in Circulation Research
Verified
Journal Article
Closed access
PDF file
VFVictoria Florea
Victoria Florea
ARAngela C. Rieger
Angela C. Rieger
DDDarcy L. DiFede
Darcy L. DiFede
JEJill El-Khorazaty
Jill El-Khorazaty
MNMakoto Natsumeda
Makoto Natsumeda
JHJoshua M. Hare
Joshua M. Hare
Rationale:: Cell dose and concentration play crucial roles in phenotypic responses to cell-based therapy for heart failure. Objective:: To compare the safety and efficacy of 2 doses of allogeneic bone marrow–derived human mesenchymal stem cells identically delivered in patients with ischemic cardiomyopathy. Methods and Results:: Thirty patients with ischemic cardiomyopathy received in a blinded manner either 20 million (n=15) or 100 million (n=15) allogeneic human mesenchymal stem cells via transendocardial injection (0.5 cc per injection × 10 injections per patient). Patients were followed for 12 months for safety and efficacy end points. There were no treatment-emergent serious adverse events at 30 days or treatment-related serious adverse events at 12 months. The Major Adverse Cardiac Event rate was 20.0% (95% confidence interval [CI], 6.9% to 50.0%) in 20 million and 13.3% (95% CI, 3.5% to 43.6%) in 100 million ( P =0.58). Worsening heart failure rehospitalization was 20.0% (95% CI, 6.9% to 50.0%) in 20 million and 7.1% (95% CI, 1.0% to 40.9%) in 100 million ( P =0.27). Whereas scar size reduced to a similar degree in both groups: 20 million by −6.4 g (interquartile range, −13.5 to −3.4 g; P =0.001) and 100 million by −6.1 g (interquartile range, −8.1 to −4.6 g; P =0.0002), the ejection fraction improved only with 100 million by 3.7 U (interquartile range, 1.1 to 6.1; P =0.04). New York Heart Association class improved at 12 months in 35.7% (95% CI, 12.7% to 64.9%) in 20 million and 42.9% (95% CI, 17.7% to 71.1%) in 100 million. Importantly, proBNP (pro-brain natriuretic peptide) increased at 12 months in 20 million by 0.32 log pg/mL (95% CI, 0.02 to 0.62; P =0.039), but not in 100 million (−0.07 log pg/mL; 95% CI, −0.36 to 0.23; P =0.65; between group P =0.07). Conclusions:: Although both cell doses reduced scar size, only the 100 million dose increased ejection fraction. This study highlights the crucial role of cell dose in the responses to cell therapy. Determining optimal dose and delivery is essential to advance the field, decipher mechanism(s) of action and enhance planning of pivotal Phase III trials. Clinical Trial Registration:: URL: http://www.clinicaltrials.gov . Unique identifier: NCT02013674.

17 July 2017 in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
Verified
Journal Article
Open access
PDF file
BTBryon A Tompkins
Bryon A Tompkins
DDDarcy L DiFede
Darcy L DiFede
AKAisha Khan
Aisha Khan
ALAna Marie Landin
Ana Marie Landin
ISIvonne Hernandez Schulman
Ivonne Hernandez Schulman
JHJoshua M. Hare
Joshua M. Hare
Aging frailty, characterized by decreased physical and immunological functioning, is associated with stem cell depletion. Human allogeneic mesenchymal stem cells (allo-hMSCs) exert immunomodulatory effects and promote tissue repair. This is a randomized, double-blinded, dose-finding study of intravenous allo-hMSCs (100 or 200-million [M]) vs placebo delivered to patients (n = 30, mean age 75.5 ± 7.3) with frailty. The primary endpoint was incidence of treatment-emergent serious adverse events (TE-SAEs) at 1-month postinfusion. Secondary endpoints included physical performance, patient-reported outcomes, and immune markers of frailty measured at 6 months postinfusion. No therapy-related TE-SAEs occurred at 1 month. Physical performance improved preferentially in the 100M-group; immunologic improvement occurred in both the 100M- and 200M-groups. The 6-minute walk test, short physical performance exam, and forced expiratory volume in 1 second improved in the 100M-group (p = .01), not in the 200M- or placebo groups. The female sexual quality of life questionnaire improved in the 100M-group (p = .03). Serum TNF-α levels decreased in the 100M-group (p = .03). B cell intracellular TNF-α improved in both the 100M- (p < .0001) and 200M-groups (p = .002) as well as between groups compared to placebo (p = .003 and p = .039, respectively). Early and late activated T-cells were also reduced by MSC therapy. Intravenous allo-hMSCs were safe in individuals with aging frailty. Treated groups had remarkable improvements in physical performance measures and inflammatory biomarkers, both of which characterize the frailty syndrome. Given the excellent safety and efficacy profiles demonstrated in this study, larger clinical trials are warranted to establish the efficacy of hMSCs in this multisystem disorder. www.clinicaltrials.gov: CRATUS (#NCT02065245).

21 April 2017 in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
Verified
Journal Article
Open access
PDF file
SGSamuel Golpanian
Samuel Golpanian
DDDarcy L DiFede
Darcy L DiFede
AKAisha Khan
Aisha Khan
ISIvonne Hernandez Schulman
Ivonne Hernandez Schulman
ALAna Marie Landin
Ana Marie Landin
JHJoshua M. Hare
Joshua M. Hare
Impaired endogenous stem cell repair capacity is hypothesized to be a biologic basis of frailty. Therapies that restore regenerative capacity may therefore be beneficial. This Phase 1 study evaluated the safety and potential efficacy of intravenous, allogeneic, human mesenchymal stem cell (allo-hMSC)-based therapy in patients with aging frailty. In this nonrandomized, dose-escalation study, patients received a single intravenous infusion of allo-hMSCs: 20-million (n = 5), 100-million (n = 5), or 200-million cells (n = 5). The primary endpoint was incidence of any treatment-emergent serious adverse events measured at 1 month postinfusion. The secondary endpoints were functional efficacy domains and inflammatory biomarkers, measured at 3 and 6 months, respectively. There were no treatment-emergent serious adverse events at 1-month postinfusion or significant donor-specific immune reactions during the first 6 months. There was one death at 258 days postinfusion in the 200-million group. In all treatment groups, 6-minute walk distance increased at 3 months (p = .02) and 6 months (p = .001) and TNF-α levels decreased at 6 months (p < .0001). Overall, the 100-million dose showed the best improvement in all parameters, with the exception of TNF-α, which showed an improvement in both the 100- and 200-million groups (p = .0001 and p = .0001, respectively). The 100-million cell-dose group also showed significant improvements in the physical component of the SF-36 quality of life assessment at all time points relative to baseline. Allo-hMSCs are safe and immunologically tolerated in aging frailty patients. Improvements in functional and immunologic status suggest that ongoing clinical development of cell-based therapy is warranted for frailty.

1 June 2021 in Journal of Hepatology
Verified
Journal Article
Closed access
DGDavid Goldberg
David Goldberg
AMAlejandro Mantero
Alejandro Mantero
CNCraig Newcomb
Craig Newcomb
CDCindy Delgado
Cindy Delgado
KFKimberly A. Forde
Kimberly A. Forde
PRPeter P. Reese
Peter P. Reese